How to appeal a UnitedHealthcare ms treatments denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for ms treatments

Cited policy: UnitedHealthcare Commercial Medical Benefit Drug Policy: Multiple Sclerosis Disease-Modifying Therapies

Diagnosis of relapsing MS confirmed by neurologist. Step therapy: trial of preferred platform DMT (interferon/glatiramer) or preferred oral (Tecfidera/Aubagio) before high-efficacy. PPMS Ocrevus requires documented PPMS with active disease. Tysabri requires TOUCH REMS + JCV testing.

How UnitedHealthcare denies ms treatments — and how to counter it

Where UnitedHealthcare pushes back: 1) Step therapy not satisfied — patient hasn't failed preferred platform/oral; 2) Lack of relapses or MRI activity in past 12 months; 3) Off-label use (rituximab for MS, Ocrevus for SPMS); 4) HSCT 'experimental/investigational'; 5) Switching high-efficacy to high-efficacy without documented failure.

Counter-arguments that hold up: AAN 2018 (reaffirmed 2022) supports DIRECT initiation of high-efficacy DMT in highly active or rapidly evolving MS. OPERA I/II showed Ocrevus superior to interferon beta-1a — requiring failure of inferior comparator contradicts pivotal evidence. Brain Health: Time Matters — every relapse and lesion is irreversible CNS injury. For PPMS: Ocrevus is the ONLY FDA-approved DMT (ORATORIO, NEJM 2017). For HSCT: MIST (JAMA 2019) - 94% disease-free at 5y vs 40%; EBMT 2020 supports HSCT as standard of care for highly active treatment-refractory RRMS.

What UnitedHealthcare typically denies for ms treatments

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For ms treatments, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the ms treatments treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Ocrevus
• Kesimpta
• Briumvi
• Tysabri
• Lemtrada
• S1P modulator

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.